Monday, November 20, 2017

© Reuters.  Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophilic esophagitis study© Reuters. Regeneron and Sanofi’s Dupixent shows treatment effect in mid-stage eosinophilic esophagitis study

  • Results from a Phase 2 clinical trial assessing Regeneron Pharmaceuticals (REGN +0.7%) and Sanofi (PA:SASY)’s (SNY +0.7%) DUPIXENT (dupilumab) in adult patients with moderate-to-severe eosinophilic esophagitis (EE) showed a treatment benefit. The data were presented at the World Congress of Gastroenterology in Orlando, FL.
  • The primary endpoint was a scale of swallowing difficulty called SDI score. At week 10, patients receiving dupilumab reported a significant improvement in the ability to swallow as measured by a three-point reduction (45% improvement) in SDI score, much better than placebo’s 19% improvement (1.3-point reduction in SDI score) (p=0.0304).
  • Dupilumab has Orphan Drug status for EE. It was approved in May for eczema.
  • Now read: Sanofi: Upward Trajectory In 2017

Original article

sponsoredArticle = ‘div-gpt-ad-1466339494851-0’;

Banner Content

FOLLOW US

GOOGLE PLUS

PINTEREST

FLICKR

INSTAGRAM

Archivies